Maia Anderson

  • Robert Davis, chief executive officer of Merck & Co., during a Bloomberg Television interview in New York, US, on Thursday, March 28, 2024. Merck won US approval for a new treatment for a rare, dangerous form of high blood pressure that’s expected to be among the company’s hits as sales from successful older drugs begin fading later this decade. Photographer: Jeenah Moon/Bloomberg via Getty ImagesHealth

    Pharma giant Merck expects Trump’s tariffs to cost the company $200 million

    By Maia Anderson and Healthcare Brew
  • Scientists working in a labFinance

    Investors are plunking billions of dollars into AI-focused biopharma companies—a more than 300% increase from 2023

    By Healthcare Brew and Maia Anderson
  • Healthcare bankruptcyFinance

    Private equity is bankrupting American healthcare firms—literally

    By Maia Anderson, Healthcare Brew, and others
  • PharmaciesHealth

    ‘This is an emergency’: Trade group warns nearly a third of all independent pharmacies will go extinct because of a CMS rule

    By Maia Anderson, Healthcare Brew, and others